The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial,fimgal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.

The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial,fimgal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.

A diffractive multi-focal lens having a diffractive structure comprising a plurality of concentric circular zones, wherein: at least a portion of the diffractive structure is provided with an overlapping region in which at least two zone profiles overlap in the same region; in the overlapping region, at least a portion of a first zone profile has a zone pitch represented by a prescribed equation, and at least a portion of a second zone profile has a zone pitch represented by another prescribed equation; and an addition power P.sub.1 given by the first zone profile and an addition power P.sub.2 given by the second zone profile are determined by a prescribed relational expression, in which a and b are mutually different real numbers, and a value of a/b cannot be expressed by a natural number X or by 1/X.

A material non-adhesive to a biological substance containing: a polymer compound (A) which includes a repeating unit derived from a sulfobetaine monomer represented by Formula (I) or (II).

##STR00001##

In the formulae, R.sup.1 represents a methyl group, an ethyl group, an n-propyl group, or an isopropyl group, a plurality of R.sup.1's may be the same as or different from each other. R.sup.2 represents a hydrogen atom or a methyl group. n represents an integer of 2 to 4. L represents a linear or branched alkylene group having 3 or 4 carbon atoms.

The disclosure provides bone graft materials, methods for their use and manufacture. Exemplary bone graft materials comprise combining a radiopaque component with a cancellous bone component to produce a bone graft material, wherein the cancellous bone component comprises native osteoreparative cells. Methods for treating a subject with the bone graft material are also provided.

To provide an agent for hypodermic injection that is unlikely to cause inflammation and to provide an injector containing the agent for hypodermic injection.

There is provided a method for producing an agent for hypodermic injection, wherein the agent includes a hydrogel containing sintered hydroxyapatite particles, and the production method includes a deaeration step for removing air contained in the agent.

The present invention provides a technique which enables organization of bone marrow cells by a simple method in a short period of time.

A method for preparing a bone marrow cell aggregate, comprising adding a liquid containing a bone marrow cell population to a medium containing a swellable material and culturing the bone marrow cell population in the presence of the swellable material. A method for reassembling a bone marrow tissue, comprising adding a liquid containing a bone marrow cell population to a medium containing a swellable material and culturing the bone marrow cell population in the presence of the swellable material.

According to common knowledge in the art, it has been considered difficult to reorganize once disintegrated bone marrow tissue without changing the cell composition (that is, without adding any adherent cell or extracellular matrix which will work as a “connecting material (binder)”). Indeed, it was impossible to aggregate bone marrow cells by conventional methods. As a result of its achievement, the present invention changes such conventional thought and results and provides a major breakthrough technique pertaining to 3D culture of bone marrow cells. It has also been confirmed that culture of a bone marrow-like tissue reassembled by the method of the present could be continued up to day 14 in the MC medium.

A method of crimping a stent is disclosed. The stent includes a minimum crimped diameter such that in the minimum crimped diameter, a pair of stent rings, between which marker support structures reside, do not make contact with the marker support structures. The crimped profile of the stent of the present invention can be as small as the crimped profile of a same stent but without the maker support structures.

A method of crimping a stent is disclosed. The stent includes a minimum crimped diameter such that in the minimum crimped diameter, a pair of stent rings, between which marker support structures reside, do not make contact with the marker support structures. The crimped profile of the stent of the present invention can be as small as the crimped profile of a same stent but without the maker support structures.

A molecular marker expressed specifically in corneal endothelial cells, and a method for producing one or more corneal endothelial cells using the marker and a method for evaluating one or more corneal endothelial cells using the marker are provided. At least one molecule selected from the group consisting of ZP4, MRGPRX3, GRIP1, GLP1R, HTR1D, and CLRN1 is used as a marker specific to corneal endothelial cells.